Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
WuXi AppTec (SS:603259), a leading Chinese pharmaceutical services company, announced plans to raise HK$7.70 billion (US$981 million) through a Hong Kong share placement to accelerate its global expansion and boost production capacity.
The company will issue 73.8 million new H-shares priced at HK$104.27 each, representing a 6.9% discount to its July 30 closing price. The placement accounts for approximately 2.51% of WuXi AppTec’s enlarged share capital and will be allocated to at least six institutional investors, according to the company’s statement.
WuXi AppTec stated that net proceeds of around HK$7.65 billion will be used mainly to fund overseas growth, with 90% earmarked for international expansion and capacity building projects. The remaining funds will be allocated for general corporate purposes.
This capital raising comes as WuXi AppTec continues to strengthen its global footprint in contract research, development, and manufacturing services amid rising demand for pharmaceutical outsourcing. The move aligns with the company’s strategy to enhance international operations and meet growing customer needs in key markets such as the United States and Europe.
The placement underscores investor confidence in WuXi AppTec’s growth prospects despite broader market volatility. By securing substantial funding, the company is positioned to expand its global infrastructure and maintain its competitive edge in the fast-evolving life sciences sector.
